Japan joins Horizon Europe: what association means for Japanese medtech, and for the European partners who want them in their consortia
Japan became the 23rd country associated to Horizon Europe on 30 July 2026. Japanese universities, research institutes and companies can now lead and be funded in Pillar II consortia on equal terms with European entities. Funding eligibility, however, is not market access — and the two are frequently confused.
Dates
Date of development: 30 July 2026 (signature and formal association)
Underlying negotiation concluded: 22 December 2025
Date of publication: 6 August 2026
Key takeaways
Japan is now formally associated to Pillar II of Horizon Europe, "Global Challenges and European Industrial Competitiveness", for award procedures implementing the Union budget from 2026 onwards. The European Commission's official participating-countries list was updated to version 4.0 on 31 July 2026 to reflect this.
The practical change is the removal of a funding barrier, not the opening of a new door. Japanese entities could always join consortia; they previously had to secure parallel domestic funding to do so. They can now be funded directly by the EU and can coordinate consortia themselves.
Japan is the most populous associated country, with 123 million people, but its historic participation is modest: 174 participations since 2021, against 1,399 from the United States. Roughly two-thirds of those were Marie Skłodowska-Curie Actions, which the association does not cover.
For medical device and diagnostics companies, the health-relevant money sits in Cluster 1 (Health), with over €1.33 billion allocated across the 2026–2027 work programme.
Association changes who can be funded. It changes nothing about MDR, IVDR, CE marking or EU market access. A device developed inside an EU-funded consortium is not, by virtue of that funding, any closer to being placed on the Union market.
What happened
On 30 July 2026, Japan became formally associated to Horizon Europe. The cooperation agreement was signed in Brussels by Hamada Takashi, Ambassador at the Mission of Japan to the European Union, and Maria Cristina Russo, Deputy Director-General for Innovation, Prosperity and International Cooperation at the European Commission's Directorate-General for Research and Innovation (DG RTD).
The Commission announced the association the same day. Its operational guidance document, the List of Participating Countries in Horizon Europe, was updated to version 4.0 on 31 July 2026, moving Japan out of the transitional-arrangements section and into the list of countries whose association agreements produce legal effects.
Negotiations concluded on 22 December 2025. Transitional arrangements have been in place since January 2026, so Japanese organisations have already been able to apply to Pillar II calls and be assessed as prospective beneficiaries. The association rests on a longer foundation: the EU–Japan Agreement on Scientific and Technological Cooperation, in force since 2011.
Commissioner for Start-ups, Research and Innovation Ekaterina Zaharieva framed the accession as Japan "strengthening a growing global community that believes openness, excellence and international cooperation are essential for transforming research into innovation and innovation into prosperity."
What is new compared with the previous position
The distinction matters, and it is routinely misreported.
Japanese entities were never excluded from Horizon Europe. They participated 174 times between 2021 and the association. What they could not do was receive EU money. A Japanese partner joining a Pillar II consortium had to line up domestic funding to cover its own costs — an arrangement Jean-Eric Paquet, the EU's ambassador to Japan and former head of DG RTD, described as "rather cumbersome" and which, on his account, scuppered some collaborations outright.
| Dimension | Before 30 July 2026 | From 30 July 2026 |
|---|---|---|
| Participation in Pillar II | Permitted | Permitted |
| Direct EU funding | No — parallel domestic funding required | Yes, on equal terms with EU entities |
| Coordinating a consortium | Not available in practice | Available |
| Counting toward minimum consortium composition | No | Yes, as an associated-country entity |
| Access to ERC and EIC | No | Still no — outside the association |
| Marie Skłodowska-Curie Actions | Open as third country | Open as third country — not covered by association |
| Financial contribution to the EU | None | Yes — approximately €6.6 million for 2026 |
Two limits deserve emphasis, because they are where expectations most often break.
First, this is a Pillar II association only. The European Research Council, which funds individual investigators, and the European Innovation Council, which backs start-ups and entrepreneurial teams, are not part of the deal. For a Japanese medtech start-up hoping for EIC Accelerator equity, nothing has changed.
Second, the Marie Skłodowska-Curie Actions are not covered — and MSCA accounted for roughly two-thirds of Japan's 174 participations. The association therefore lands on the part of the programme where Japan has historically been least active.
Why this matters in practice
Japan's contribution for 2026 is approximately €6.6 million, around 0.05% of the programme's expected budget for the year. For context, that is three times New Zealand's first-year bill of €2.1 million, despite Japan having roughly twenty-three times the population. It is a modest opening number, and it reflects the low Pillar II participation base rather than any ceiling on ambition. New Zealand's second-year contribution more than doubled to €5 million; a similar trajectory for Japan in 2027 and 2028 is plausible but unconfirmed.
The strategic case is stronger than the arithmetic.
Japan brings a deep and under-tapped industrial research base. The Japanese medical device market was valued at approximately USD 34.2 billion in 2025, and Japanese manufacturers hold globally significant positions in exactly the segments where EU health research is concentrated: Olympus in endoscopy, Terumo in cardiovascular and interventional devices, Sysmex in haematology and laboratory diagnostics, Canon Medical Systems and Fujifilm in imaging, Nihon Kohden in patient monitoring, alongside Hoya, Shimadzu, Nipro and Asahi Intecc. These are not peripheral players, and until now none of them could be funded as a Horizon Europe beneficiary.
The public research hubs are equally substantial. RIKEN and AIST are among the world's larger public research organisations; JST and JSPS are the principal science funders; AMED is the dedicated medical research funding agency. The EU–Japan Centre for Industrial Cooperation has served as Japan's Horizon Europe National Contact Point since the Ministry of Foreign Affairs appointed it at the end of 2021.
For medtech specifically, the funds are in Cluster 1. The Health cluster's 2026–2027 work programme, published on 12 December 2025, carries over €1.33 billion, structured as a small number of large topics across six destinations — the health–climate nexus, non-communicable diseases, mental health, antimicrobial resistance and pandemic preparedness among them. Single-stage calls have closed on 16 April and 15 September 2026, with further topics opening in 2027.
There is a candid counterweight. Pillar II is not the programme's most admired component. It has been criticised as bureaucratic and slow to disburse, and evaluators have found limited measurable effect on participating companies' revenues. Under the successor framework programme beginning in 2028, Pillar II's share is projected to fall from 54% to 43.4% of the budget, even as the absolute figure rises to around €76 billion. Japan, like Canada, New Zealand and the Republic of Korea, has joined a part of the programme that is proportionally shrinking — and its participation in the successor programme will require fresh negotiation.
Who is affected
Japanese medical device, IVD and digital health manufacturers seeking European research partnerships and EU funding
Japanese universities, RIKEN, AIST and other research institutes now able to coordinate consortia rather than merely join them
European coordinators building Cluster 1 consortia, who gain a materially larger pool of fundable partners
EU-based medtech SMEs looking for Japanese clinical, manufacturing or precision-engineering partners
Contract research organisations and clinical investigation sites in both jurisdictions
Regulatory and quality functions on both sides, who will inherit the consequences of consortium decisions made without regulatory input
Dates and deadlines
| Date | Event |
|---|---|
| 2011 | EU–Japan Agreement on Scientific and Technological Cooperation enters into force |
| 12 December 2025 | Cluster 1 (Health) work programme 2026–2027 published |
| 22 December 2025 | EU and Japan conclude association negotiations |
| 1 January 2026 | Transitional arrangements begin; Japan added to Commission list v3.7 |
| 30 July 2026 | Association signed and takes effect; Japan becomes 23rd associated country |
| 31 July 2026 | Commission participating-countries list updated to v4.0 |
| 2027–2028 | Japanese contribution expected to rise; figures not yet published |
| 2028 | Successor framework programme begins; Japan's participation requires fresh negotiation |
Practical actions to consider
For Japanese organisations:
Confirm eligibility scope before building a proposal. Association covers Pillar II and the institutionalised European partnerships, for award procedures implementing the Union budget from 2026 onwards. It does not cover ERC, EIC or MSCA.
Decide early whether to coordinate or partner. Coordination is now available and carries real strategic weight, but also administrative and financial-reporting obligations that most Japanese institutions have not previously carried.
Engage the EU–Japan Centre as National Contact Point before committing resource to a proposal.
Separate the funding question from the market-access question at the outset. They run on different timelines, different legal instruments and different evidence requirements.
For European coordinators:
Re-examine partner shortlists. Japanese entities that were previously ruled out on funding grounds are now fundable, and several are world-leading in the relevant technology areas.
Build regulatory strategy into the consortium agreement, not after it. Where a consortium expects to generate a device, diagnostic or software product, decide early who owns the regulatory pathway, who will act as legal manufacturer, and how clinical data generated in the project will be structured to support a future conformity assessment.
For both:
Do not assume EU-funded clinical data automatically supports an MDR or IVDR submission. Data generated for a research objective is not necessarily data structured for a clinical evaluation. Retro-fitting it is expensive.
Uncertainties and open questions
Japan's contribution for 2027 and 2028 has not been published. The €6.6 million figure is drawn from a draft 2026 budget and covers this year only.
Uptake is genuinely uncertain. Piero Carninci, an Italian geneticist at RIKEN with extensive EU consortium experience, has said he does not expect a surge of Japanese applications, citing limited awareness and the language barrier around the programme's rules. Paquet takes a more optimistic view, noting that Japanese university leadership was closely involved in the negotiations.
Participation in the post-2028 successor programme is not settled. A Japanese official quoted by Science|Business said Tokyo "will carefully consider Japan's position while monitoring EU discussions."
The interaction between Horizon Europe grant obligations and regulatory strategy is not addressed anywhere in the association documentation. Open-science, dissemination and exploitation obligations under the grant agreement can sit awkwardly with the confidentiality and design-control expectations of a regulated product development programme. This is a live practical issue and manufacturers should not assume it resolves itself.
QLE perspective
The most consequential thing about this announcement is also the least discussed: association is a research-funding instrument and nothing more. It does not confer regulatory status, shorten a conformity assessment, or create any presumption of compliance.
We raise this because we see the confusion repeatedly. A Japanese manufacturer that develops a device inside an EU-funded Pillar II consortium still needs, in order to place that device on the Union market, a conformity assessment under Regulation (EU) 2017/745 or Regulation (EU) 2017/746, a designated EU authorised representative, a person responsible for regulatory compliance, EUDAMED registration, and a technical file that will withstand notified body scrutiny. None of that is furnished by the grant. The consortium's research timeline and the regulatory timeline are separate, and the second is usually longer.
The corollary is an opportunity. Consortia that bring regulatory thinking in at proposal stage — rather than at the point where a promising result needs a route to market — tend to produce clinical evidence that is usable twice: once for the project deliverable, and once for the eventual submission. That is a design decision made in month one, not month thirty.
Our second observation is about consortium composition. Japanese association meaningfully widens the partner pool for European coordinators in imaging, endoscopy, diagnostics and precision manufacturing — areas where Japanese capability is strong and where EU consortia have often had to work around a funding constraint. Coordinators re-running their partner analysis this autumn will find options that were not practical a year ago.
Where we would counsel caution: the modest size of Japan's opening contribution and the historic concentration of Japanese activity in MSCA rather than Pillar II both suggest that volume will build slowly. Organisations should plan for a gradual widening of the partner pool rather than a step change.
Conclusion
Does Japan's association to Horizon Europe change anything for medtech? Yes, on the research side, and concretely: from 30 July 2026 Japanese companies and institutes can be funded directly by the EU, can coordinate Pillar II consortia, and can be counted toward consortium composition — with over €1.33 billion in Cluster 1 (Health) across 2026–2027 as the most relevant target. On the market-access side it changes nothing at all. The organisations that will extract the most value from this are those that treat the two as one strategic question from the beginning rather than two sequential problems.
Working with QLE
QLE Group BV advises medical device and diagnostics organisations in Brussels and internationally on EU regulatory strategy, quality management systems and market access.
For organisations acting on Japan's association, three areas of our work are directly relevant:
Fractional regulatory support — senior regulatory and quality capability on a defined, part-time basis, for Japanese manufacturers building an EU regulatory function for the first time, and for consortium partners who need regulatory input without a permanent hire.
Consortium building and partner assessment — identifying and qualifying partners across the EU and Japan, and structuring the regulatory workstream within a Horizon Europe proposal so that project deliverables and future conformity assessment requirements are aligned from the outset.
Strategic consultancy — EU market-entry strategy, classification and conformity-assessment route selection, authorised representative and PRRC arrangements, and clinical evidence strategy under the MDR and IVDR.
If you are preparing a Cluster 1 proposal with a Japanese partner, or are a Japanese organisation assessing what association makes possible, we are glad to discuss the regulatory dimension before the consortium agreement is signed.
Side note: the 23 countries associated to Horizon Europe
Association is not uniform. Several countries are associated only to Pillar II, and several only for award procedures from a specified budget year onwards. The list below follows the Commission's official List of Participating Countries in Horizon Europe, version 4.0, dated 31 July 2026.
| # | Country | Scope of association |
|---|---|---|
| 1 | Albania | Full programme |
| 2 | Armenia | Full programme |
| 3 | Bosnia and Herzegovina | Full programme |
| 4 | Canada | Pillar II only, incl. institutionalised European partnerships; budget year 2024 onwards |
| 5 | Egypt | Full programme; budget year 2025 onwards |
| 6 | Faroe Islands | Full programme |
| 7 | Georgia | Full programme |
| 8 | Iceland | Full programme |
| 9 | Israel | Full programme |
| 10 | Japan | Pillar II only, incl. institutionalised European partnerships; budget year 2026 onwards |
| 11 | Kosovo | Full programme |
| 12 | Moldova | Full programme |
| 13 | Montenegro | Full programme |
| 14 | New Zealand | Pillar II only, incl. institutionalised European partnerships; Work Programmes 2023 onwards |
| 15 | North Macedonia | Full programme |
| 16 | Norway | Full programme |
| 17 | Republic of Korea | Pillar II only, incl. institutionalised European partnerships; budget year 2025 onwards |
| 18 | Serbia | Full programme |
| 19 | Switzerland | Full programme; budget year 2025 onwards |
| 20 | Tunisia | Full programme |
| 21 | Türkiye | Full programme |
| 22 | Ukraine | Full programme |
| 23 | United Kingdom | Full programme except the EIC Fund; budget year 2024 onwards (EIC Fund via transitional arrangements, 2026 onwards) |
Source: European Commission, List of Participating Countries in Horizon Europe, version 4.0, 31 July 2026.
Transitional arrangements currently apply to: Morocco (entire programme) and the United Kingdom (EIC Fund only, for award procedures implementing the Union budget from 2026 onwards).
In the pipeline: the EU and Australia formally opened association negotiations on 31 March 2026 and concluded them on 9 June 2026. Singapore has also been in discussions. Liechtenstein has stated it does not intend to associate to Horizon Europe.
Euratom Research and Training Programme: association agreements with Switzerland and Ukraine are producing legal effects. Switzerland is associated to the entire Euratom programme for budgetary commitments from 2025 onwards.
Sources
European Commission — Japan officially joins Horizon Europe (IP/26/1705, 30 July 2026)
European Commission — List of Participating Countries in Horizon Europe, v4.0, 31 July 2026 (PDF)
European Commission — International cooperation with Japan in research and innovation
European Commission — Horizon Europe Work Programme 2026–2027, Part 4: Health
EEAS — EU and Japan successfully conclude negotiations on Horizon Europe Association
Eunews — Japan joins the EU's Horizon Europe research programme (30 July 2026)
Science|Business — What Japan's association means for Horizon Europe (8 January 2026)
Science|Business — Japan and EU sign off Horizon Europe association (30 July 2026)
EU–Japan Centre for Industrial Cooperation — Horizon Europe National Contact Point
